Stock Analysis
Cegedim (EPA:CGM) Full Year 2023 Results
Key Financial Results
- Revenue: €616.0m (up 11% from FY 2022).
- Net loss: €7.41m (down by 154% from €13.6m profit in FY 2022).
- €0.54 loss per share (down from €1.00 profit in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cegedim EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.
Looking ahead, revenue is forecast to grow 5.6% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
Performance of the market in France.
The company's shares are down 17% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Cegedim, and understanding this should be part of your investment process.
Valuation is complex, but we're helping make it simple.
Find out whether Cegedim is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:CGM
Cegedim
Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals in France, other European countries, and internationally.
Very undervalued with adequate balance sheet.